CHICAGO, August 13, 2015 /PRNewswire/ --
According to a new market research report "In-Situ Hybridization Market by Type (DNA, RNA), by Application (Cancer, Diagnosis, Cytology, Immunology), by End User (Hospitals, Pharma & Biotech, Research Labs), by Geography - Analysis and Forecast to 2019", the global In-Situ Hybridization Market was valued at $554.4 Million 2014, and is estimated to reach $681.0 Million by 2019, at a CAGR of 4.2% during the forecast period, 2014 to 2019.
Browse 40 Tables and 35 Figures spread through 182 Slides and in-depth TOC on "In-Situ Hybridization Market"
Early buyers will receive 10% customization on this report.
In situ hybridization is used to locate and detect specific nucleic acids, such as mRNA and DNA or protein sequences in morphologically preserved tissues or cell preparations by hybridizing the complementary strand of a nucleotide probe to the sequence of interest. The growth of the global In-Situ Hybridization Market can be attributed to increasing prevalence of cancer along with the growing usage of personalized medicines for its treatment.
Ask For PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=212028829
The global In-Situ Hybridization Market is expected to witness substantial growth in the near future. There is a growing adoption of in-situ hybridization in various sectors, such as cancer diagnostics, cytology, neurosciences, immunology, and others. The cancer diagnostics segment led the market in 2014, and is expected grow at a CAGR of 4.7% from 2014 to 2019. Hospitals, pharma & biotech companies, research labs, CROs, and others constituted the end user segment of the global in-situ hybridization market. Among the end users, the hospitals segment acquired the largest share of 49.6% of the global in-situ hybridization market.
The global In-Situ Hybridization Market is mainly driven by the increasing incidences of cancer across the globe. For instance, According to GLOBOCAN project, which estimates incidence, mortality, and prevalence from major types of cancer, in 2012, the number of cancer-related deaths and new cancer cases across the world was 8.2 Million and 14.1 Million respectively. International Agency for Research on Cancer (ICRA) and the World Health Organization (WHO) estimated that 19.3 Million new cancer cases will be diagnosed every year by 2025, Based on GLOBOCAN's statistics. In-situ hybridization, due to its reliability in terms of qualitative as well as quantitative evaluation of the biomarker is mainly used for the diagnosis and management of cancer disease. With the rising incidences of these diseases worldwide, the market for in-situ hybridization is expected to witness substantial growth in the near future.
The research study is aimed at identifying emerging trends and opportunities in the global In-Situ Hybridization Market along with detailed classifications, in terms of revenue. It provides comprehensive competitive landscape and identifies the key players with respect to market size and market share. The research study also includes a detailed segmentation of the global in-situ hybridization market, on the basis of type, application, end user, and geography.
Apart from the market segmentation, this report also makes use of the Porter's Five Forces Analysis, which provides an in-depth analysis of the market providing a detailed process flow diagram and market dynamics, such as drivers, restraints, and opportunities in the global in-situ hybridization market.
Browse Related Reports:
Flow Cytometry Market by Technology (Cell & Bead-based), Products & Services (Reagents, Instruments, Software, & Accessories), Application (Research & Clinical), End User (Commercial Organizations & Diagnostics Laboratories) - Global Forecasts to 2018.
Tissue Diagnostics Market by Technology (Immunohistochemistry, in Situ Hybridization, Digital pathology & Workflow, Special Staining), Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer and Others), Product (Instruments and Consumables), End-Users (Hospitals, Pharmaceutical companies, Research Laboratories, Contract Research Organizations and Others) & by Region (The Americas, Europe, BRIC, Japan & RoW) - Trends & Forecast to 2018.
MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
1 South Dearborn Street,
21st Floor, Chicago,
Illinois, 60603, United States,
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets